# A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Study · id `cardio:ct-nct01809327` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01809327](<https://clinicaltrials.gov/study/NCT01809327>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01809327

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1186 participants.

## Technical summary

Registry record NCT01809327. Randomized; quadruple masking; primary purpose treatment. Start 2013-06-04 (actual); primary completion 2014-12-02 (actual). Results posted on 2016-01-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1186 participants (enrolled count; ClinicalTrials.gov record NCT01809327, source copy `cardio:ctgov-nct01809327-2017-07-11`, retrieved 2026-10-26)
- Started: 2013-06-04 (actual) (ClinicalTrials.gov record NCT01809327, source copy `cardio:ctgov-nct01809327-2017-07-11`, retrieved 2026-10-26)
- Primary completion: 2014-12-02 (actual) (ClinicalTrials.gov record NCT01809327, source copy `cardio:ctgov-nct01809327-2017-07-11`, retrieved 2026-10-26)
- Completion: 2014-12-02 (actual) (ClinicalTrials.gov record NCT01809327, source copy `cardio:ctgov-nct01809327-2017-07-11`, retrieved 2026-10-26)
- Results first posted: 2016-01-06 (ClinicalTrials.gov record NCT01809327, source copy `cardio:ctgov-nct01809327-2017-07-11`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; Czechia; Hungary; Mexico; Puerto Rico; Romania; Russia; Slovakia; South Africa; South Korea; Ukraine (ClinicalTrials.gov record NCT01809327, source copy `cardio:ctgov-nct01809327-2017-07-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01809327-2017-07-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Canagliflozin 100 mg
- Intervention (Drug): Canagliflozin 300 mg
- Intervention (Drug): Metformin XR
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes (`cardio:pubmed-26786577`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f71efc37cd8cd57e12b4e2ef1cc7c02e6e32e5de0b95926741f7b05f2206a64b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
